MARKET

RGLS

RGLS

Regulus Therapeu
NASDAQ
1.400
+0.090
+6.87%
Closed 16:00 12/01 EST
OPEN
1.340
PREV CLOSE
1.310
HIGH
1.400
LOW
1.280
VOLUME
9.31K
TURNOVER
0
52 WEEK HIGH
2.140
52 WEEK LOW
0.7600
MARKET CAP
28.31M
P/E (TTM)
-0.8791
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RGLS last week (1120-1124)?
Weekly Report · 6d ago
Weekly Report: what happened at RGLS last week (1113-1117)?
Weekly Report · 11/20 10:20
Weekly Report: what happened at RGLS last week (1106-1110)?
Weekly Report · 11/13 10:16
Regulus Stock Maintains Buy Rating Amid Financial Stability and Positive Clinical Trial Progress
TipRanks · 11/10 17:16
Whitney Ijem Reaffirms Buy Rating for Regulus (RGLS) Based on Q3 Results and Promising Clinical Trials
TipRanks · 11/10 16:40
Regulus Therapeutics GAAP EPS of -$0.40
Regulus therapeutics reported q3 gaap eps of -$0.40. The company had $30.8 million in cash, cash equivalents and short-term investments as of september 30, 2023. Regulus has a lead asset in kidney disease.
Seeking Alpha · 11/10 16:06
Regulus Therapeu: Current report
Press release · 11/09 23:19
Regulus Therapeu: Quarterly report
Press release · 11/09 23:19
More
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat diseases. The Company is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s lead product candidate includes RGLS8429. The Company is developing single-stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are complementary to (thereby pairing with) the target microRNA. RGLS8429 is an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). RGLS8429 maintains beneficial attributes, such as preferential kidney exposure and similar PK profile, miR-17 inhibition potency and duration of action in the kidney, equal potency in vitro and in vivo efficacy studies.

Webull offers Regulus Therapeutics Inc stock information, including NASDAQ: RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.